Literature DB >> 15930551

Bone morphogenetic proteins. Development and clinical efficacy in the treatment of fractures and bone defects.

M F Termaat1, F C Den Boer, F C Bakker, P Patka, H J Th M Haarman.   

Abstract

The discovery of bone morphogenetic proteins marks a major step forward in the understanding of bone physiology and in the development of advanced methods in skeletal surgery. The cornerstones for successful growth-factor therapy in skeletal surgery remain biomechanical stability and biological vitality of the bone providing an adequate environment for new bone formation. Knowledge of the biological characteristics, mechanisms of action, and methods of delivery of growth factors will become essential for skeletal surgeons. The current clinical application of bone morphogenetic proteins is safe and efficacious as a result of a well-regulated cascade of events leading to bone formation. Clinical trials have not yet determined whether different clinical indications each require a specific bone-tissue-engineering format or if a single pathway for stimulating bone-healing with growth factors is sufficient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930551     DOI: 10.2106/JBJS.D.02585

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  44 in total

Review 1.  Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence.

Authors:  P V Giannoudis; N K Kanakaris; T A Einhorn
Journal:  Osteoporos Int       Date:  2007-08-12       Impact factor: 4.507

Review 2.  Gene therapy approaches to regenerating bone.

Authors:  Nadav Kimelman Bleich; Ilan Kallai; Jay R Lieberman; Edward M Schwarz; Gadi Pelled; Dan Gazit
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

3.  Mesenchymal stem cells with increased stromal cell-derived factor 1 expression enhanced fracture healing.

Authors:  Chih-Yuan Ho; Anita Sanghani; Jia Hua; Melanie Coathup; Priya Kalia; Gordon Blunn
Journal:  Tissue Eng Part A       Date:  2014-11-13       Impact factor: 3.845

4.  Long-term safety and efficacy of human bone morphogenetic protein (HBMP) in the treatment of resistant non-unions and failed arthrodesis.

Authors:  Arya Nick Shamie; Hamed Yazdanshenas; Eric Egan Johnson
Journal:  J Clin Orthop Trauma       Date:  2016-11-16

5.  Adipose-derived stem cells and BMP-2 delivery in chitosan-based 3D constructs to enhance bone regeneration in a rat mandibular defect model.

Authors:  Jiabing Fan; Hyejin Park; Matthew K Lee; Olga Bezouglaia; Armita Fartash; Jinku Kim; Tara Aghaloo; Min Lee
Journal:  Tissue Eng Part A       Date:  2014-05-09       Impact factor: 3.845

6.  Management of subtrochanteric femur fractures with internal fixation and recombinant human bone morphogenetic protein-7 in a patient with osteopetrosis: a case report.

Authors:  Robert D Golden; Edward K Rodriguez
Journal:  J Med Case Rep       Date:  2010-05-19

Review 7.  Growth factors in bone repair.

Authors:  Valentina Devescovi; Elisa Leonardi; Gabriela Ciapetti; Elisabetta Cenni
Journal:  Chir Organi Mov       Date:  2008-11-29

8.  The synergistic effect of autograft and BMP-7 in the treatment of atrophic nonunions.

Authors:  Peter V Giannoudis; Nikolaos K Kanakaris; Rozalia Dimitriou; Ian Gill; Vinod Kolimarala; Richard J Montgomery
Journal:  Clin Orthop Relat Res       Date:  2009-04-24       Impact factor: 4.176

9.  BMP2 is essential for post natal osteogenesis but not for recruitment of osteogenic stem cells.

Authors:  M V Bais; N Wigner; M Young; R Toholka; D T Graves; E F Morgan; L C Gerstenfeld; T A Einhorn
Journal:  Bone       Date:  2009-05-03       Impact factor: 4.398

10.  Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures.

Authors:  Neil Ghodadra; Kern Singh
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.